MA
Therapeutic Areas
Glenmark Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GBR 310 | Oncology/Immunology (Undisclosed) | Phase 1 |
| GBR 830 | Immunology (Undisclosed) | Phase 2 |
| ISB 830 | Oncology (Undisclosed) | Preclinical |
| Biosimilar Portfolio | Various Oncology & Immunology | Varies |
Leadership Team at Glenmark Pharmaceuticals
MG
Mr. Glenn Saldanha
Chairman & Managing Director
MM
Mr. Marc T. Kikuchi
President & Business Head – North America